ACADIA Pharmaceuticals/$ACAD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
- Ticker
- $ACAD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 797
- Headquarters
- San Diego, United States
- Website
- acadia.com
ACAD Metrics
BasicAdvanced
$3.5B
9.33
$2.21
0.85
-
Price and volume
Market cap
$3.5B
Beta
0.85
52-week high
$30.96
52-week low
$18.39
Average daily volume
2M
Financial strength
Current ratio
3.388
Quick ratio
3.107
Long term debt to equity
0.046
Total debt to equity
0.057
Profitability
EBITDA (TTM)
98.228
Gross margin (TTM)
62.06%
Net profit margin (TTM)
33.42%
Operating margin (TTM)
7.59%
Effective tax rate (TTM)
-213.50%
Revenue per employee (TTM)
$1,430,000
Management effectiveness
Return on assets (TTM)
3.64%
Return on equity (TTM)
35.74%
Valuation
Price to earnings (TTM)
9.334
Price to revenue (TTM)
3.078
Price to book
2.7
Price to tangible book (TTM)
2.95
Price to free cash flow (TTM)
24.068
Free cash flow yield (TTM)
4.15%
Free cash flow per share (TTM)
0.855
Growth
Revenue change (TTM)
11.75%
Earnings per share change (TTM)
66.40%
3-year revenue growth (CAGR)
27.38%
10-year revenue growth (CAGR)
143.25%
3-year earnings per share growth (CAGR)
47.31%
10-year earnings per share growth (CAGR)
1.35%
What the Analysts think about ACAD
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
Analyst projections of the future price of ACADIA Pharmaceuticals stock.
Bulls say / Bears say
DAYBUE is gaining traction: second-quarter sales rose 30% to $125 million, driven by STIX uptake, and Acadia raised its 2026 DAYBUE sales outlook to $480–510 million. (Acadia Pharmaceuticals)
NUPLAZID is showing renewed volume momentum: second-quarter sales grew 10% on an adjusted basis and new-patient prescriptions rose 20%, reaching their highest quarterly level since the first quarter of 2018 as the expanded sales force took effect. (The Motley Fool)
A newly allowed US patent could extend DAYBUE protection to March 2041, strengthening the franchise’s long-term commercial runway if the patent is issued. (Yahoo Finance)
Remlifanserin, a potential future growth driver, narrowly missed its Phase 2 primary endpoint, with a p-value of 0.0603; its continued Phase 3 development still carries meaningful efficacy risk. (Reuters)
Nuplazid generic-protection litigation remains unresolved: appeals by generic manufacturers are pending and a further Zydus trial was scheduled for November 2026, creating uncertainty around the durability of a major revenue stream. (Acadia Pharmaceuticals)
Profitability remains modest relative to the company’s commercial spending: second-quarter net income was $32 million on $308 million of revenue, while 2026 SG&A is guided at $660–700 million and R&D at $355–380 million. (Acadia Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
ACAD Financial Performance
Revenues and expenses
ACAD Earnings Performance
Company profitability
Upcoming events
No upcoming events
ACAD News
AllArticlesVideos
Funds containing ACAD
AllUSDEURGBP
Fund name | Fund size | $ACAD weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.25% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.25% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.25% |
iShares Ageing Population$AGED | $953M | 0.23% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.23% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.